Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Blood (2024) 144 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2024-205407

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Annalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, Inmaculada Peiro Martinez, Felipe Peña, Lidia Hurtado, Raquel Lopez Gil, Alberto Mussetti, Montserrat Arnan, Helena Pomares, Eva Gonzalez Barca, Patricia Lopez Pereira, Rocky Strollo, Paolo Pozzilli, Anna Sureda Balari

Blood (2024) 144 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2024-198124

Published: 2024

Journal Articles

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Blood (2024) 144 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2024-198114

Published: 2024

Journal Articles

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Blood (2024) 144 (Supplement 1): 597.

https://doi.org/10.1182/blood-2024-207189

Published: 2024

Journal Articles

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Julia Ribes-Amoros, Helena Pomares, Susana Vives, Nuria Brey, Jordi Verge, Rosa Coll, Marta Cervera, Elena Bechtold Javier, Shiomara Quiñones, Maria Isabel Sotelo, Mercedes Galiano, Esther Alonso, Anna Sureda Balari, Lurdes Zamora, Isabel Granada, Montserrat Arnan

Blood (2024) 144 (Supplement 1): 6138.

https://doi.org/10.1182/blood-2024-205868

Published: 2024

Journal Articles

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Blood (2024) 144 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2024-211133

Published: 2024

Journal Articles

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2024-204557

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Helena Pomares, Iago Arribas, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundi, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 4225.

https://doi.org/10.1182/blood-2023-178351

Published: 2023

Journal Articles

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2023-178885

Published: 2023

Journal Articles

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Blood (2023) 142 (Supplement 1): 6477.

https://doi.org/10.1182/blood-2023-180680

Published: 2023

Journal Articles

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Iago Arribas, Helena Pomares, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes-Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundí, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5930.

https://doi.org/10.1182/blood-2023-189187

Published: 2023

Journal Articles

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Blood (2023) 142 (Supplement 1): 6425.

https://doi.org/10.1182/blood-2023-184980

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Blood (2023) 142 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2023-179234

Published: 2023

Journal Articles

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

Helena Pomares, Villarreal Hernandez Jasson, Susana Vives, Marta Cervera, Rosa Coll, Lurdes Zamora, Clara Maluquer, Gladys Ibarra, Julia Ribes Amoros, Georgina Gener-Ricós, Mercedes Galiano, Anna Sureda, Montserrat Arnan Sangerman

Blood (2022) 140 (Supplement 1): 9021–9022.

https://doi.org/10.1182/blood-2022-168819

Published: 2022

NARROW

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only